Angiotensin II in General Anesthesia
Hypertension
About this trial
This is an interventional treatment trial for Hypertension focused on measuring Angiotensin II, Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, Anesthesia-Mediated Hypotension
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of hypertension and treatment with at least one medication including an ACE inhibitor, ARB, and other agents for greater than 2 months
- Patients undergoing general anesthesia
Exclusion Criteria:
- BMI > 40
- History of deep venous thrombosis / thromboembolic disease
- History of stroke,
- Baseline SBP of ≥ 160 mmHg,
- History of myocardial infarction or cardiac stents
- Difficult airway
- Asthma
- Congestive heart failure
- Chronic obstructive pulmonary disease
- Pregnant patients
Sites / Locations
- Wake Forest Baptist Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Participants on ACE inhibitors
Participants on ARBs
Other Classes of Antihypertensive Agents
Participants taking ACE inhibitors (angiotensin-converting enzyme inhibitors)will be placed into this group. Intervention: Drug: Angiotensin II.
Participants taking ARBs (angiotensin-receptor blockers) will be placed into this group. Intervention: Drug: Angiotensin II.
Participants taking any other class of Antihypertensive Agents will be placed into this group. Intervention: Drug: Angiotensin II.